Favorable Response to Long-Term Azithromycin Therapy in Bronchiectasis Patients with Chronic Airflow Obstruction Compared to Chronic Obstructive Pulmonary Disease Patients without Bronchiectasis

References

• Mullerova H, Maselli DJ, Locantore N, et al. Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. Chest. 2015;147(4):999–1007. doi:10.1378/chest.14-0655
   PubMed Web of Science ®Google Scholar
• Spencer S, Calverley PM, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J. 2004;23(5):698–702. doi:10.1183/09031936.04.00121404
   PubMed Web of Science ®Google Scholar
• Hoogendoorn M, Hoogenveen RT, Rutten-van Molken MP, Vestbo J, Feenstra TL. Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach. Eur Respir J. 2011;37(3):508–515. doi:10.1183/09031936.00043710
   PubMed Web of Science ®Google Scholar
• López-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology. 2016;21(1):14–23. doi:10.1111/resp.12660
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Report; 2020. Available from: www.goldcopd.org. Accessed April 6, 2020.
   Google Scholar
• Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689–698. doi:10.1056/NEJMoa1104623
   PubMed Web of Science ®Google Scholar
• Uzun S, Djamin RS, Kluytmans JA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014;2(5):361–368. doi:10.1016/S2213-2600(14)70019-0
   PubMed Web of Science ®Google Scholar
• Han MK, Tayob N, Murray S, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med. 2014;189(12):1503–1508. doi:10.1164/rccm.201402-0207OC
   PubMed Web of Science ®Google Scholar
• Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA. 2013;309(12):1251–1259. doi:10.1001/jama.2013.1937
   PubMed Web of Science ®Google Scholar
• Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA. 2013;309(12):1260–1267. doi:10.1001/jama.2013.2290
   PubMed Web of Science ®Google Scholar
• Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):660–667. doi:10.1016/S0140-6736(12)60953-2
   PubMed Web of Science ®Google Scholar
• Polverino E, Goeminne PC, McDonnell MJ, et al. European respiratory society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3):3. doi:10.1183/13993003.00629-2017
   Web of Science ®Google Scholar
• Hill AT, Sullivan AL, Chalmers JD, et al. British Thoracic Society Guideline for bronchiectasis in adults. Thorax. 2019;74(Suppl 1):1–69.
   Web of Science ®Google Scholar
• O’Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax. 2000;55(8):635–642. doi:10.1136/thorax.55.8.635
   PubMed Web of Science ®Google Scholar
• Martínez-García MA, de la Rosa Carrillo D, Soler-Cataluña JJ, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(8):823–831. doi:10.1164/rccm.201208-1518OC
   PubMed Web of Science ®Google Scholar
• Mao B, Lu H-W, Li M-H, et al. The existence of bronchiectasis predicts worse prognosis in patients with COPD. Sci Rep. 2015;5(1):10961. doi:10.1038/srep10961
   PubMedGoogle Scholar
• Du Q, Jin J, Liu X, Sun Y, Sethi S. Bronchiectasis as a comorbidity of chronic obstructive pulmonary disease: a systematic review and meta-analysis. PLoS One. 2016;11(3):e0150532. doi:10.1371/journal.pone.0150532
   PubMed Web of Science ®Google Scholar
• Choi H, Yang B, Nam H, et al. Population-based prevalence of bronchiectasis and associated comorbidities in South Korea. Eur Respir J. 2019;54(2):1900194. doi:10.1183/13993003.00194-2019
   PubMed Web of Science ®Google Scholar
• Ringshausen FC, de Roux A, Diel R, Hohmann D, Welte T, Rademacher J. Bronchiectasis in Germany: a population-based estimation of disease prevalence. Eur Respir J. 2015;46(6):1805–1807. doi:10.1183/13993003.00954-2015
   PubMed Web of Science ®Google Scholar
• Aksamit TR, O’Donnell AE, Barker A, et al. Adult patients with bronchiectasis: a first look at the US bronchiectasis research registry. Chest. 2017;151(5):982–992. doi:10.1016/j.chest.2016.10.055
   PubMed Web of Science ®Google Scholar
• Hansell DM, Bankier AA, MacMahon H, McLoud TC, Muller NL, Remy J. Fleischner society: glossary of terms for thoracic imaging. Radiology. 2008;246(3):697–722. doi:10.1148/radiol.2462070712
   PubMed Web of Science ®Google Scholar
• Zhou Y, Wang C, Yao W, et al. COPD in Chinese nonsmokers. Eur Respir J. 2009;33(3):509–518. doi:10.1183/09031936.00084408
   PubMed Web of Science ®Google Scholar
• Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34(3):648–654. doi:10.1183/09031936.00102509
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med. 2014;189(5):576–585. doi:10.1164/rccm.201309-1575OC
   PubMed Web of Science ®Google Scholar
• Miller M. ATS/ERS task force: standardisation of spirometry. Eur Respir J. 2005;26(2):319–338. doi:10.1183/09031936.05.00034805
   PubMed Web of Science ®Google Scholar
• Choi JK, Paek D, Lee JO. Normal predictive values of spirometry in Korean population. Tuberc Respir Dis. 2005;58(3):230–242. doi:10.4046/trd.2005.58.3.230
   Google Scholar
• Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948–968. doi:10.1183/09031936.05.00035205
   PubMed Web of Science ®Google Scholar
• Kon SS, Canavan JL, Jones SE, et al. Minimum clinically important difference for the COPD assessment test: a prospective analysis. Lancet Respir Med. 2014;2(3):195–203. doi:10.1016/S2213-2600(14)70001-3
   PubMed Web of Science ®Google Scholar
• Martinez-Garcia MA, Polverino E, Aksamit T. Bronchiectasis and chronic airway disease: it is not just about asthma and COPD. Chest. 2018;154(4):737–739. doi:10.1016/j.chest.2018.02.024
   PubMed Web of Science ®Google Scholar
• Spagnolo P, Fabbri LM, Bush A. Long-term macrolide treatment for chronic respiratory disease. Eur Respir J. 2013;42(1):239–251. doi:10.1183/09031936.00136712
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Curtis JL, Albert R. Role of macrolide therapy in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008;3(3):331–350. doi:10.2147/COPD.S681
   PubMedGoogle Scholar
• Suzuki T, Yanai M, Yamaya M, et al. Erythromycin and common cold in COPD. Chest. 2001;120(3):730–733. doi:10.1378/chest.120.3.730
   PubMed Web of Science ®Google Scholar
• Seemungal TAR, Wilkinson TMA, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008;178(11):1139–1147. doi:10.1164/rccm.200801-145OC
   PubMed Web of Science ®Google Scholar
• Naderi N, Assayag D, Mostafavi-Pour-Manshadi SM, et al. Long-term azithromycin therapy to reduce acute exacerbations in patients with severe chronic obstructive pulmonary disease. Respir Med. 2018;138:129–136. doi:10.1016/j.rmed.2018.03.035
   PubMed Web of Science ®Google Scholar
• Cui Y, Luo L, Li C, Chen P, Chen Y. Long-term macrolide treatment for the prevention of acute exacerbations in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2018;13:3813–3829. doi:10.2147/COPD.S181246
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Boersma W, Lonergan M, et al. Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis. Lancet Respir Med. 2019;7(10):845–854. doi:10.1016/S2213-2600(19)30191-2
   PubMed Web of Science ®Google Scholar
• Henkle E, Curtis JR, Chen L, et al. Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis. Eur Respir J. 2019;54(1):1. doi:10.1183/13993003.01896-2018
   Web of Science ®Google Scholar
• Gatheral T, Kumar N, Sansom B, et al. COPD-related bronchiectasis; independent impact on disease course and outcomes. Copd. 2014;11(6):605–614. doi:10.3109/15412555.2014.922174
   PubMedGoogle Scholar
• Martínez-García M, Soler-Cataluña JJ, Donat Sanz Y, et al. Factors associated with bronchiectasis in patients with COPD. Chest. 2011;140(5):1130–1137. doi:10.1378/chest.10-1758
   PubMed Web of Science ®Google Scholar
• Patel IS, Vlahos I, Wilkinson TM, et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170(4):400–407. doi:10.1164/rccm.200305-648OC
   PubMed Web of Science ®Google Scholar
• Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359(22):2355–2365. doi:10.1056/NEJMra0800353
   PubMed Web of Science ®Google Scholar
• Patel IS, Seemungal TA, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax. 2002;57(9):759–764. doi:10.1136/thorax.57.9.759
   PubMed Web of Science ®Google Scholar
• Simpson JL, Powell H, Baines KJ, et al. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLoS One. 2014;9(8):e105609. doi:10.1371/journal.pone.0105609
   PubMed Web of Science ®Google Scholar
• Brill SE, Law M, El-Emir E, et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax. 2015;70(10):930–938. doi:10.1136/thoraxjnl-2015-207194
   PubMed Web of Science ®Google Scholar
• Rogers GB, Bruce KD, Martin ML, Burr LD, Serisier DJ. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial. Lancet Respir Med. 2014;2(12):988–996. doi:10.1016/S2213-2600(14)70213-9
   PubMed Web of Science ®Google Scholar